Clinical trial
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
NCT04419649 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Lead sponsor
- Takeda
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 19, 2020
- Completion date
- October 30, 2031
- Enrollment
- 160 (estimated)
- Sites
- 53
Conditions
As the registry lists them; a condition with its own page is linked.